Vanda Pharmaceuticals Inc. (VNDA)

16.65
0.01 0.06
NASDAQ
Prev Close 16.64
Open 16.65
Day Low/High 16.13 / 16.79
52 Wk Low/High 13.88 / 33.44
Volume 405.92K
Exchange NASDAQ
Shares Outstanding 52.64B
Market Cap 917.04M
Div & Yield N.A. (N.A)
Surprising Approval for Vanda's Fanapt

Surprising Approval for Vanda's Fanapt

The approval of Vanda's drug Fanapt for schizophrenia by the Food and Drug Administration sent shares of the company leaping more than 800% in Wednesday's after-hours trading session.

Bank Of America, Boeing, Macy's Big Movers

Bank Of America, Boeing, Macy's Big Movers

Bank of America, Boeing, Macy's, Symantec among big market movers Thursday

Stock Search: BofA, Citigroup, DryShips, AIG

Stock Search: BofA, Citigroup, DryShips, AIG

Bank of America and Citigroup once again topped the list of today's most-searched-for stocks on TheStreet.com. Newcomers to the list include Cadence Design, J.P. Morgan, Cisco Systems, State Street and Vanda Pharmaceuticals.

Vanda Shares Peak After Fanapt Gets FDA Approval

Vanda Shares Peak After Fanapt Gets FDA Approval

FDA approves Vanda Pharmaceuticalss schizophrenia drug, and stock rockets in heavy trading

Premarket Roundup: Fifth Third, Vanda Pharma

Premarket roundup: Fifth Third Bancorp jumps after upgrade, Vanda Pharma up on drug approval

Ahead Of The Bell: Vanda Surges On Fanapt Approval

Vanda shares soar after company says FDA approves schizophrenia drug following delay

Latest News in Activist Investing

Activist investors are clamoring for change at companies such as AP Pharma and Lions Gate.

This Week's 'Barron's' Roundup

This Week's 'Barron's' Roundup

The latest dividend changes, and going bullish on Northern Trust and Hewlett-Packard.

Biotech Mailbag 2008 Review

Here's a look back at the hits, misses and notable moments from 2008.

Feuerstein's Biotech-Stock Mailbag: Titan

Feuerstein's Biotech-Stock Mailbag: Titan

Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.

Feuerstein's Biotech-Stock Mailbag: Elan

Feuerstein's Biotech-Stock Mailbag: Elan

Revaluing a severely beaten Elan. And wanted: Your votes on best biotech CEO.

Health Winners & Losers: Amgen

Health Winners & Losers: Amgen

Amgen climbs on phase III study results of denosumab.

Vanda Sinks on FDA Rejection (Update)

Vanda Sinks on FDA Rejection (Update)

Its lead drug, antipsychotic iloperidone, will require another clinical trial and more safety data before approval.

Vanda Pharma Sinks on FDA Rejection

Vanda Pharma Sinks on FDA Rejection

Its lead drug, antipsychotic iloperidone, will require another clinical trial and more safety data before approval.

Vanda Sleep Drug Data Sedate Investors

A late-stage study of tasimelte meets its primary endpoint but not secondary ones related to sleep maintenance.

Biotech-Stock Mailbag: Sangamo

Biotech-Stock Mailbag: Sangamo

Weighing chances for Sangamo's lead pipeline drug, and more.

Biotech Notebook: Vertex, Medicines Co.

Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.

Health Winners & Losers: Tercica

Tercica soars on news of a $663 million buyout.

Friday's Winners & Losers: Yahoo!

Shares rise 6.9% on more merger rumors.

Friday's Health Winners & Losers

Discovery Labs falls on another regulatory delay for its Surflaxin.

Feuerstein's Biotech-Stock Mailbag

BioSante Pharma's chief takes on the critics.

Feuerstein's Biotech Mailbag

This week, Adam responds to reader inquiries about Xoma, Vanda and Onyx.

Wednesday's Health Winners & Losers

QLT climbs on news it's looking into 'strategic alternatives.'

Thursday's Health Winners & Losers

Pozen rises.

Thursday's Small-Cap Winners & Losers

Flotek sinks.

Friday's Health Winners & Losers

Celera rises.

Vanda Rises on Offering

It raises $96 million.

Markets Break for Jobs

Markets dip as traders await a crucial jobs report.

Thursday's Health Winners & Losers

Tercica jumps.

Vanda Surges on Study Results

The update is on experimental antipsychotic drug iloperidone.

TheStreet Quant Rating: C+ (Hold)